Replies to post #398638 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

One needs to understand the difference between a PR and a clinal data presentation slide deck.

The latter is what has gone missing.

This may explain why people don’t understand where the wholes in the P2b/3 data is.

[bb8675309]

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
Plan to Meet with Regulatory Authorities to Determine Next Steps.

Anavex 2-73 Winner...This study result should have a $5 to $10 Billion share price MC.